Regenxbio Inc
RGNXHealthcare|Biotechnology|USA
$13.95
-1.71 (-10.92%)
Tangible Book
$0.41
Clinical Trials (23)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07236606 RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) | MPS II, Hunter Syndrome (MPS II) | P3 | Active | 2 | Open-label | — |
| NCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | AMD, nAMD | P3 | Recruiting | 714 | RCT, Double-blind | Aflibercept (EYLEA®) |
| NCT03566043 CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) | Mucopolysaccharidosis Type II (MPS II) | P2P3 | Active | 48 | Open-label | — |
| NCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | AMD, nAMD | P2P3 | Active | 671 | RCT, Double-blind | Ranibizumab (LUCENTIS®) |
| NCT05693142 AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | P2P3 | Recruiting | 65 | Open-label | — |
| NCT04567550 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) | Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME) | P2 | Active | 139 | RCT, Single-blind | Topical Steroid, Aflibercept |
| NCT06942520 Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME) | Diabetic Macular Edema | P2 | Recruiting | 18 | RCT, Open-label | Aflibercept (2.0 mg) |
| NCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-Related Macular Degeneration (nAMD) | P2 | Active | 146 | RCT, Single-blind | Ranibizumab, Local Steroid, Topical Steroid |
| NCT05683379 AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD | Duchenne Muscular Dystrophy | Active | 200 | — | — | |
| NCT03066258 Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial | Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration | P1P2 | Completed | 42 | Open-label | — |
| NCT04571970 RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) | Mucopolysaccharidosis Type II (MPS II) | P1P2 | Completed | 6 | Open-label | — |
| NCT03580083 RGX-111 Gene Therapy in Patients With MPS I | Mucopolysaccharidosis Type I (MPS I), Hurler Syndrome | P1P2 | SUSPENDED | 21 | Open-label | — |
| NCT02651675 A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH) | Homozygous Familial Hypercholesterolemia (HoFH) | P1P2 | Terminated | 9 | Open-label | — |
| NCT06491927 Long Term Follow-up for RGX-202 | Duchenne Muscular Dystrophy | By Invite | 66 | — | — | |
| NCT04591834 Mucopolysaccharidosis Type II Observational | Mucopolysaccharidosis II | Withdrawn | — | — | — | |
| NCT03529786 Mucopolysaccharidosis Type II Natural History | Mucopolysaccharidosis II | Completed | 36 | — | — | |
| NCT04597385 Long-term Follow-Up for RGX-121 | Mucopolysaccharidosis II | Unknown | 12 | — | — | |
| NCT04080050 A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501 | Homozygous Familial Hypercholesterolemia (HoFH) | Unknown | 8 | — | Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy | |
| NCT04480476 A Retrospective, Natural History Study in Children With CLN2 | Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) | Withdrawn | — | — | — | |
| NCT07652606 Expanded Access to RGX-202 | TEMPORARILY_NOT_AVAILABLE | — | — | — | ||
| NCT04462692 An Observational Study in Children With CLN2 Batten Disease | Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) | Withdrawn | — | — | — | |
| NCT06103487 Long Term Follow-Up for RGX-111 | Mucopolysaccharidosis I | By Invite | 21 | — | — | |
| NCT04148001 Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients | Homozygous Familial Hypercholesterolemia (HoFH) | Completed | 4 | — | — |